ClinicalTrials.gg
Active, not recruitingNCT05262400Updated Sep 14, 2026

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

A Phase 1/2 interventional study of PF-07220060 + PF-07104091 combination dose escalation and PF-07220060 + PF-07104091 combination dose escalation in Breast Cancer and Solid Tumors, sponsored by Pfizer. Active, not recruiting at 44 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
235
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.

Enrollment
30th of 121
235 · median 75
Started
2022
with 9 others
Phase 1/2
13 of 182
none open now
Primary completion
2027-02
later than 12 of 25 live
Registered
143rd of 182
by date

Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 30th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2022, is one of 13 in phase 1/2, reaches primary completion later than 12 of the 25 other live ones, and was the 143rd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who:

  • Have been diagnosed with Breast Cancer (BC) of either types:
  • Have HR+, HER2- BC
  • Refractory HR-positive/HER2-positive BC
  • Have other solid tumors other than BC

In part 2, we are seeking participants who:

-Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.

03

Conditions studied

  • Breast Cancer
  • Solid Tumors

Browse trials for

Keywords

  • cyclin-dependent kinase 2 (CDK2)
  • cyclin-dependent kinase 4 (CDK4)
  • estrogen receptor-positive/human epidermal growth factor receptor 2 negative (ER+/HER2-)
  • estrogen receptor-positive/refractory hormone receptor positive (ER+/HER2+)
  • hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Breast Cancer (BC)
  • HR+, - BC
  • HR-positive/HER2-positive BC
  • Part 1: Solid Tumors other than BC
  • Part 2:
  • HR-positive/HER2-negative BC
  • Lesion:
  • Part 1: evaluable lesion (including skin or bone lesion only)
  • Part 2: per v1.1
  • Prior systemic Treatment
  • Part 1: HR-positive/HER2-negative BC
  • At least 1 line of SOC, including CDK4/6 inhibitor therapy and Endocrine Therapy, for advanced or disease.
  • Prior chemotherapy in the metastatic setting is allowed.
  • Part 1: HR-positive/HER2-positive BC
  • At least 1 prior treatment of approved HER2 targeting therapy.
  • Part 1: Solid Tumors other than BC
  • Participants with no standard therapy available or for which no local regulatory approved standard therapy is available that would confer significant clinical benefit in the medical judgement of the investigator.
  • Part 2A: At least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and ET.
  • Parts 2B: At least 1 prior endocrine therapy for advanced or metastatic disease. Progression during treatment or within 12 months of completion of endocrine therapy is acceptable.
  • Part 2B: Up to 1 for advanced/metastatic disease is allowed.
  • General Inclusion Criteria
  • (ECOG) Performance Status (PS) 0 or 1
  • Adequate renal, liver, and bone marrow function
  • Resolved acute effects of any prior therapy to baseline severity

Exclusion criteria

Exclusion Criteria:

  • All Study Parts: Permanent treatment discontinuation from prior CDK 4 and/or CDK2 inhibitor due to treatment related toxicity.
  • Part 2B and 1C: Prior treatment with any CDK 4/6 inhibitor, or SERDs (e.g. fulvestrant), or everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway for advanced disease.
  • Parts 2B and 2C: Prior treatment with any CDK4/6 inhibitor for advanced disease.
  • Parts 2B and 2C: Prior treatment with an endocrine therapy for advanced disease.
  • Part 2C: Prior or adjuvant treatment with a nonsteroidal aromatase inhibitor AI (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment.
  • Part 2C: Any prior systemic treatment for advanced disease.
  • Prior irradiation to >25% of the bone marrow
  • Current use of drugs which have a risk for prolongation
  • Current use or anticipated need for food or drugs that are known strong /5, strong UGT2B7 or UGT1A9 inhibitors or inducers
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry

    • Participants with any other active within 3 years prior to enrollment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease
    • Major surgery within 4 weeks prior to study entry
    • Radiation therapy within 4 weeks prior to study entry.
    • hypertension
    • Known or suspected to PF-07220060, PF-07104091, letrozole, fulvestrant, or goserelin (or equivalent to induce chemical menopause if applicable)
  • Known abnormalities in coagulation. Anticoagulation with subcutaneous heparin or prophylactic doses of anticoagulant are allowed
  • Known active uncontrolled or symptomatic central nervous system (CNS)
  • Active inflammatory GI disease
  • Current use or anticipated need for Proton Pump Inhibitors (PPI) within 14 days prior to first dose of the study intervention
  • Previous high-dose chemotherapy requiring stem cell rescue
  • Participants with active, uncontrolled bacterial, fungal, or viral infection, including virus (HBV), virus (HCV), and known (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  • Other protocol specific exclusion criteria may apply
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    Part 1 Dose Escalation - Dose Level 4

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 2A

    PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and Endocrine Therapy)

    Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion

  • Experimental
    Part 1 Dose Escalation - Dose Level 3

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 2B

    PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior endocrine therapy and up to 1 prior line of chemotherapy for advanced or metastatic disease and no prior treatment with any CDK4/6 inhibitor for advanced disease)

    Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion

  • Experimental
    Part 1 Dose Escalation - Dose Level 5

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 2C

    PF-07220060 + PF-07104091 + Letrozole (ER+/HER2- Breast Cancer with no prior treatment with any CDK4/6 inhibitor for advanced disease)

    Drug: PF-07104091 + PF-07220060 + letrozole dose expansion

  • Experimental
    Part 1 Dose Escalation - Dose Level 2

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 1 Dose Escalation - Dose Level 1

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 1 Dose Escalation - Dose Level 6

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 1 Dose Escalation - Dose Level 7

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

  • Experimental
    Part 1 Dose Escalation - Dose Level 8

    PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)

    Drug: PF-07220060 + PF-07104091 combination dose escalation

Interventions

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07104091 + PF-07220060 + fulvestrant dose expansion

    PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

  • DrugPF-07104091 + PF-07220060 + fulvestrant dose expansion

    PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

  • DrugPF-07104091 + PF-07220060 + letrozole dose expansion

    PF-07104091 and PF-07220060 will be administered orally in combination with letrozole

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

  • DrugPF-07220060 + PF-07104091 combination dose escalation

    PF-07104091 and PF-07220060 will be administered orally

This study also gives Fulvestrant. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle

    Number of participants with DLTs, which are typically Grade 3 or higher adverse events will be summarized by dose level

    Time frame: Cycle 1 (28 days)

  2. Number of participants with treatment emergent adverse events (AEs)

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  3. Incidence of participants with clinical laboratory abnormalities

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  4. Number of participants with vital signs abnormalities

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

  5. Number of participants with corrected QT (QTc) interval

    Determine the effect of the drug on QT prolongation. The number and percentage of participants who experienced QT interval prolongation will be summarized by dose level

    Time frame: From baseline until end of study treatment or study completion (approximately 2 years)

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of PF-07220060 and PF-07104091 together after a single dose and multiple dose

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  2. Time to maximum plasma concentration (Tmax) of PF-07220060 and PF-07104091 together after a single dose and multiple dose

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  3. Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-07220060 and PF-07104091 together

    Time frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)

  4. Objective response rate (ORR) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    Percentage of participants with a best ORR of complete response (CR) or partial response (PR) using RECIST 1.

    Time frame: From baseline through disease progression or study completion (approximately 2 years)

  5. To evaluate the preliminary antitumor activity of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole by time to event endpoints

    Time from first assessment of event endpoint to last assessment of using RECIST 1.1

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

  6. Duration of Response (DoR) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    DoR is defined as the time from first documentation of CR or PR to date of first documentation of progressive disease/pharmacodynamic (PD) or death due to any cause, whichever occurs first

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

  7. Progression-Free Survival (PFS) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

  8. Time to Progression (TTP) of PF-07220060 and PF-07104091 together in dose escalation and together in combination with fulvestrant or letrozole

    TTP is defined as the time from start date of treatment to the date of the first documentation of PD

    Time frame: From baseline through time to event on study or study completion (approximately 2 years)

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Feb 2027, 59 months after the start.

Of 163 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 59 months is close to that.

Counting every sponsor, half of 330 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 2, 2022
StartActual
Mar 14, 2022
Primary completionEst.
Feb 26, 2027
CompletionEst.
Feb 26, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05262400
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Mar 14, 2022
Primary completion
Feb 26, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion